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Abstract
Peroxisome proliferator-activated receptor γ (PPARγ) is a well-known target for thiazolidine-
dione antidiabetic drugs. In this paper, we present the synthesis and biological evaluation of
a series of dihydropyrano[2,3-c]pyrazole derivatives as a novel family of PPARγ partial ago-
nists. Two analogues were found to display high affinity for PPARγ with potencies in the
micro molar range. Both of these hits were selective against PPARγ, since no activity was
measured when tested against PPARα, PPARδ and RXRα. In addition, a novel modelling
approach based on multiple individual flexible alignments was developed for the identifica-
tion of ligand binding interactions in PPARγ. In combination with cell-based transactivation
experiments, the flexible alignment model provides an excellent analytical tool to evaluate
and visualize the effect of ligand chemical structure with respect to receptor binding mode
and biological activity.
Introduction
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors
of the nuclear hormone receptor superfamily [1]. Many cellular and systemic roles have been
attributed to these receptors, reaching far beyond the stimulation of peroxisome proliferation
in rodents after which they were initially named. The three PPAR subtypes PPARα, PPARδ
and PPARγ exhibit broad, subtype-specific tissue expression patterns. The PPARγ subtype is
most highly expressed in adipose tissue, and agonists for this receptor, increase adipocyte dif-
ferentiation, enhance insulin sensitivity and improve lipid profiles [2,3]. A variety of synthetic
agonists for PPARγ have been studied in the area of antidiabetic drug discovery (Fig 1), such
as the full agonists thiazolidinediones (TZDs), including rosiglitazone (1) and pioglitazone (2).
These drugs are now well established in clinical practice for the treatment of type II diabetes.
However, despite their effectiveness in lowering blood glucose levels and improving insulin
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sensitivity [4], they have recently been associated with severe side effects, such as fluid reten-
tion, weight gain, cardiac hypertrophy, and hepatotoxicity [5,6]. Strong evidence suggest that
these side-effects may be associated with full agonism, and much recent focus has been given
to the development of partial agonists, which are expected to retain full insulin sensitizing
effects with minimal side-effects [5,6]. One such partial agonist, balaglitazone (3), was shown
to activate PPARγ and improve glucose levels without causing undesirable accumulation of
fluid and fat [7].
In view of these developments, the discovery of novel selective PPARγ agonists with partial
binding properties would be advantageous not only as candidates for the treatment of type II
diabetes, but also as chemical probes to investigate the function of PPARγ, as new roles for it
are currently being identified, e.g. as anti-obesity drug target [8].
Recently, we reported [9] an integrated in silico / in vitro workflow, based on pharmaco-
phore- and structure-based virtual screening of the ZINC library, coupled with competitive
binding and transactivation assays, and adipocyte differentiation and gene expression studies.
In this study, dihydropyrano[2,3-c]pyrazole 4 was identified as a promising PPARγ partial ago-
nist combining high inhibitor activity (IC50 = 0.03 mM) with a relatively poor induction of
adipocyte differentiation. This promoted us to further investigate the dihydropyrano[2,3-c]
pyrazoles as a novel class of PPARγ ligands. Herein, we present the development of a synthe-
tically tractable scale-up synthesis of dihydropyrano[2,3-c]pyrazole 4 for further biological
studies. Furthermore, we describe the synthesis and biological evaluation of a series of novel
dihydropyrano[2,3-c]pyrazole derivatives with high structural variation.
Results and discussion
1. Chemistry
1.1 Dihydropyrano[2,3-c]pyrazoles. Dihydropyrano[2,3-c]pyrazoles constitute an
important class of compounds with a wide range of biological properties, such as anticancer
[10], antimicrobial [11] and anti-inflammatory [12] activities. Only recently, we published
data that identified the dihydropyrano[2,3-c]pyrazole 4 as a promissing PPARγ partial agonist
for the treatment of type II diabetes.
The most common and convenient approach towards diverse dihydropyrano[2,3-c]pyra-
zoles is a two-step procedure (Fig 2) comprising the following steps: (1) Condensation of
Fig 1. Pharmacologically relevant PPARγ ligands.
doi:10.1371/journal.pone.0162642.g001
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hydrazine derivative 5 is condensensed with β-keto ester 6 under basic conditions to produce
the 1H-pyrazol-5(4H)-one derivative 7; (2) Three-component base-catalyzed reaction of 1H-
pyrazol-5(4H)-one 7, aromatic aldehyde 8 and malononitrile 9. The three-component reaction
involve a tandem Michael addition-Thorpe-Ziegler-type reaction, followed by tautomerization
[13] to generate the dihydropyrano[2,3-c]pyrazole core 10. It should be noted that these com-
pounds may exist in the 1,4-dihydro or 2,4-dihydro tautomeric forms when the N1 position is
unsubstituted (R1 = H).
The presented protocol represents a synthetically tractable strategy for drug discovery as
the target molecule is synthesized in two high-yielding steps without the need for time-con-
suming chromatography. Furthermore, the general two-step sequence (Fig 2) is easily amena-
ble to the preparation of combinatorial libraries of diverse dihydropyrano[2,3-c]pyrazoles.
Given the large number of commercially available aldehydes and the easy access to hydrazines
and β-keto esters, this method provides access to dihydropyrano[2,3-c]pyrazole libraries with
high appendage diversity introduced through substituents at the 1-, 3-, and 4-positions.
1.2 Scale-up synthesis of lead compound 4. Dihydropyrano[2,3-c]pyrazole 4 is a pro-
missing PPARγ partial agonist, that may serve as an entry for the development of new antidia-
betics. We initiated our studies by developing a practical and gram-scale synthesis of 4 for
compound validation, further medicinal chemistry evaluation, and lead optimization studies.
Considering the synthetic strategy outlined in Fig 2, aldehyde building block 15 constitutes
a key intermediate for the scale-up synthesis of 4. The readily available bromomethylbenzalde-
hyde 14 was identified as the most readily available precursor to aldehyde 15. Our stepwise
synthesis of 14 commenced with m-xylene, which was bis-chloromethylated to afford 1,5-bis
(chloromethyl)-2,4-dimethylbenzene 12 [14]. This was then converted to dialdehyde 13 in a
Sommelet reaction, following a procedure developed by Wood [15]. Selective reduction of one
of the aldehyde moieties with NaBH4 and subsequent treatment of the resulting monoalcohol
with HBr in boiling AcOH afforded the bromomethylbenzaldehyde 14 [16]. Compound 14
was quantitatively converted to aldehyde 15 by reaction with 4-chloro-2-methylphenol in ace-
tonitrile at 50˚C in the presence of K2CO3.
With substantial amounts of key intermediate 15 in hand, we investigated the final tandem
Michael addition-Thorpe-Ziegler reaction (Fig 2) to generate the desired dihydropyrano[2,3-
c]pyrazole. Reactant 17 [17] was easily available from ethyl acetoacetate and hydrazine hydrate
(90% yield after re-crystallization). Finally, treatment of 17 with aldehyde 14 and malononitrile
in EtOH resulted in precipitation of 4 [18] directly from the reaction mixture as a pure, white
powder in 72% yield (Fig 3).
Fig 2. Reaction pathway for the synthesis of dihydropyrano[2,3-c]pyrazole derivatives 10.
doi:10.1371/journal.pone.0162642.g002
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1.3 Synthesis of 1,4-dihydropyrano-[2,3-c]pyrazoles. Next, the two-step protocol was
applied to prepare a collection of 1,4-dihydropyrano[2,3-c]pyrazoles. All starting hydrazines
were purchased from commercial suppliers. The corresponding β-keto esters were synthesized
either according to Yuasa and Tsuruta [19] or by deprotonation of esters and subsequent reac-
tion with ethyl acetate [20]. Aldehydes were all purchased or prepared in one step from 14
according to the procedure described for the synthesis of 15. Following the general procedure
(Fig 2), a library of 32 structurally diverse 1,4-dihydropyrano[2,3-c]pyrazoles were synthesized
(Fig 4). The ease of this procedure should be emphasized. The reaction was performed at 80˚C
for 2 h and upon cooling to room temperature, nearly all products precipitated as discrete
powders with no need for further purification.
2. Biological evaluation
2.1 Competitive binding and transactivation assays. The dihydropyrano[2,3-c]pyrazoles
4, 10a-10ag were tested for transactivation and affinity from competitive binding assay (Fig 4).
Twenty-three of the dihydropyrano[2,3-c]pyrazoles dose-dependently displaced a labeled
PPARγ ligand in vitro in a TR-FRET competitive binding assay. Potency of binding as com-
pared with known PPAR ligands was ranging from low affinity, as for compound 10c, 10g, 10h,
10aa and 10ad with IC50 > 100 μM, to fairly high affinity, as observed for compound 10ae and
10af (IC50 1 μM) (Fig 4). Rosiglitazone was measured to displace with an IC50 of 58 nM in
this assay, in agreement with previously reported affinities [21]. Further, to examine receptor
binding at a more functional level, we analysed the ability of the compounds to induce tran-
scriptional activation in a cell based transactivation assay. Fourteen compounds were found to
stimulate PPARγ-mediated transactivation (Fig 4). As several relatively potent binders (com-
pounds 10b, 10f and 10ag) did not induce transcriptional activation, we speculated whether
these compounds were behaving as antagonists. However, both cellular uptake and compound
“metabolism” could influence the actual concentration, and it cannot be excluded that some of
the compounds did not reach saturating concentrations in the cell-based transactivation assay.
It was indeed observed that most of the tested dihydropyrano[2,3-c]pyrazole compounds
showed some activity against the PPARγ receptor, with the exception of compounds 10e, 10j,
Fig 3. Reaction pathway for the synthesis of dihydropyrano[2,3-c]pyrazole 4. (i) Parafomaldehyde, AcOH, conc. HCl
(aq), 70˚C, 48 h (37%); (ii) hexamethylenetetramine, EtOH, H2O, reflux, 16 h (37%); (iii) (a) NaBH4, EtOH, (b) HBr, AcOH;
(iv) 4-chloro-2-methylphenol. K2CO3, CH3CN, 50˚C, 3 h (99%); (v) hydrazine hydrate, EtOH, 0˚C to 60˚C, 3 h (90%); (vi)
malonitrile, Et3N, EtOH, 80˚C, 17 min (72%).
doi:10.1371/journal.pone.0162642.g003
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10k, 10l, 10z, 10ab and 10ac. In analogy with previous SAR analyses of PPARγ interacting
compound series, the resulting SAR is not easily interpreted. However, it appears that the
2,5-dimethylaryl (10a, 10g, 10p, 10ab, 10ae) and the N1 4-Cl-phenyl moieties (10ae, 10af) are
structural elements that confer transactivation to the dihydropyranozole scaffold. Further-
more, a strong correlation was observed between structure and binding affinity for the com-
pounds, with the two NI 4-chlorophenyl-substituted dihydropyrano[2,3-c]pyrazoles (10ae and
10af) both being identified as high-affinity binders with potency in the micro molar range.
The two most potent hits (10ae and 10af) were further tested for transactivation selectivity
towards all three PPAR subtypes. Both of the hits were found to be selective against PPARγ.
2.2 Evaluation of PPARγ binding mode. The binding modes of the dihydropyrano[2,3-
c]pyrazoles 4, 10a-10ag were explored with the multiple individual alignment approach [22],
[23]. For this purpose, a model set of PPARγ template ligands was generated on the basis of
PPARγ agonist-receptor complexes from the Protein Data Bank (PDB). More specifically, the
template set was created from twenty-three PDB PPARγ ligands accounting eleven full and
twelve partial agonists (see S1 File). Each template was made from an agonist-bound PPARγ
structure and removal of the receptor leaving the template agonist in its crystal conformation.
Fig 4. Chemical and biological data for dihydropyrano[2,3-c]pyrazoles.
doi:10.1371/journal.pone.0162642.g004
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Afterwards, individual alignment attempts of a given test molecule on each of the generated
templates followed by reintroduction of the receptor and energy calculation, provided a hit list
of matching binding modes. According to the targets encoded by these templates, a binding
profile for the test ligand was generated.
In order to identify and implement rational threshold values for the docking screen, all
twenty-three known PPARγ model ligands were docked with the procedure described above. It
was found that all model-ligands could be identified by their own template. To prioritize the best
hits and reduce the number of false positives, the internal strain (dU), configurational similarity
(dF) and alignment score (dS) constraints were set to a threshold value of 1. Furthermore, only
compounds with an Autodock docking score (ΔG) more negative than a threshold value of -10
kcal/mol passed the docking screen, while any remaining compounds were discarded.
To validate the model, a test set of twenty-four known PPARγ ligands, including nine full
agonists, seven partial agonists, and eight inactives, was collected from the literature (see S2
File). The set of agonists was constituted by known antidiabetic drugs, including rosiglitazone
(1, TZD), farglitazar (non-TZD) and other biological relevant agonist with either selective
PPARγ or dual PPARα/γ, PPARδ/γ selectivity, but no pan PPAR agonists were included. It
was ensured that the compounds covered a broad range of activities, from weak to medium
and strong agonists. The inactives were manually selected from a set of PPARγ inactive com-
pounds that were structurally similar to the selected PPARγ agonists. Upon evaluation of the
test set of PPARγ ligands in the model, seven of the nine full agonists were found to match a full
agonist template (with the exception of CID-11384748 and CID-44411945) with four of them
matching on more than one template. Six out of seven partial agonists were observed to align
on a partial agonist template (with the exception of CID-15069295). Unfortunately, due to the
high structural similarity between actives and inactives, the model was not always able to dis-
criminate between the two, leading to several of the inactive test compounds being identified as
actives (false positives). However, in combination with cell-based transactivation experiments,
the presented model provides a promising analytical tool to evaluate and visualize the effect of
ligand chemical structure in respect to receptor binding mode and biological activity.
Next, the methodology was applied to the reference dihydropyrano[2,3-c]pyrazole PPARγ
partial agonist 4. The ligand 4 was found to match two of the partial agonist templates (CID-
2742752 and CID-10229498). From further inspection of the suggested binding modes, it was
concluded that the CID-10229498 binding mode is reasonable (Fig 5). The dihydropyrano
[2,3-c]pyrazole group of 4 was observed to make several stabilizing hydrophobic interactions
in the β-sheet regions, while the amino group formed a hydrogen bond with Ile281 located in
Helix3. Furthermore, the central benzene ring made strong interactions with Cys285.
Finally, we analysed the binding modes of 32 novel potential PPARγ partial agonists (10a-
10ag) by incorporation in twenty-three ligand templates in the individual alignment model.
Of the 32 compounds analysed by the model, we were able to identify binding modes for
twenty-one of them. All ligands without identifiable binding modes were found to be low
affinity binders (IC50 < 30 mM) in the ligand displacement experiments.
Six of the dihydropyrano[2,3-c]pyrazole compounds (10q, 10r, 10s, 10ae, 10af and 10ag)
displaying highest transactivation potential were found to match the same CID-10229498
template as reference dihydropyrano[2,3-c]pyrazole 4. A closer inspection of the docked
ligands revealed that although all of the six ligands matched the same template, they clustered
around two distinct binding modes. A strong correlation between binding mode and chemical
structure was observed. The ligands 10q, 10r and 10s share high structural similarity with
dihydropyrano[2,3-c]pyrazole 4 and were all observed to have identical alignments in the
CID-10229498 template displaying the same types of interactions as described for 4. However,
the presence of a substituent on the dihydropyrano[2,3-c]pyrazole N1 clearly influences the
Dihydropyrano-[2,3-c]pyrazoles as a new class of PPARγ partial agonists
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receptor ligand complex. The high-affinity ligands 10ae, 10af and 10ag have a N1 phenyl-sub-
stituent in common. Although they were recognized to match the CID-10229498 template,
they seemed to adopt a different but mutually similar scaffold positioning (Fig 6). The altered
ligand structure induces a relocation of the ligand in the receptor, allowing the dihydropyranol
[2,3-c]pyrazole phenyl-group to participate in several stabilizing hydrophobic interactions
with Ser342 and Ile341 in the β-sheet regions. The altered positioning places the pyrano[2,3-c]
pyrazole moiety in close proximity to Helix3, where strong interactions with Cys285 are
observed. Furthermore, the carbonitrile group may interact with Arg288.
Conclusions
In here we report dihydropyrano[2,3-c]pyrazoles as a novel class of PPARγ partial agonists. A
synthetically tractable scale-up synthesis of lead compound dihydropyrano[2,3-c]pyrazole 4
has been developed for compound validation as well as further medicinal chemistry efforts.
Furthermore, the synthesis and biological evaluation of a series of novel dihydropyrano[2,3-c]
pyrazole derivatives with high structural variation has been accomplished. Competitive bind-
ing and transactivation assay experiments showed that most of the compounds displayed some
activity against PPARγ with the two NI 4-chlorophenyl-substituted dihydropyrano[2,3-c]pyra-
zoles (10ae and 10af) both being identified as selective high-affinity binders with potency in
the micro molar range.
Moreover, a novel approach based on multiple individual flexible alignment for the identifi-
cation of ligand binding interactions in PPARγ was developed. In combination with cell-based
transactivation experiments, the flexible alignment model provides an excellent analytical tool
to evaluate and visualize the effect of ligand chemical structure in respect to receptor binding
mode and biological activity.
Experimental section
1. Materials and measurements
All reagents used were commercially available. All solvents were of HPLC grade. Analytical
LC-MS analysis was performed on a Waters AQUITY UPLC system equipped with PDA and
Fig 5. The ligand 4 presented in the aligned binding mode on CID-10229498.
doi:10.1371/journal.pone.0162642.g005
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SQD MS detector; column: AQUITY UPLC BEH C18 1.7μm, 2.1 x 50mm; column temp:
65˚C; solvent A: 0.1% formic acid (aq); solvent B: 0.1% formic acid (acetonitrile); gradient: 5%
B to 100% B in 2.4 min, hold for 0.1 min, total run-time ca. 2.6 min. 1H and 13C NMR 300
MHz spectra were recorded on a Varian Mercury 300 BB spectrometer at room temperature.
All NMR spectra were recorded using CDCl3 or DMSO-d6 as solvents
2. Synthesis
2.1 1,3-Bis(chloromethyl)-4,6-dimethylbenzene (12) [15]. A stirred solution of m-
xylene (100.0 mL, 0.818 mol), paraformaldehyde (58.0 g, 1.93 mol), acetic acid (99%, 200 mL)
and conc. HCl (aq, 800 mL) was mechanical stirred for 48 h at 70˚C. During the last part of the
reaction time (18 h), the product precipitated as a white solid. The reaction mixture was cooled
to room temperature, and the product isolated by filtration. The filter cake was washed with
water and then dissolved in boiling heptane (200 mL). The boiling heptane phase was washed
with hot 10% aqueous NaHCO3 (50 mL) and then phase separated. Upon cooling to room
temparature, the product precipitated as a white solid. Yield: 60.3 g (37%). 1H NMR (300
MHz, CDCl3): δ = 7.26 (s, 1H, ArH), 7.06 (s, 1H, ArH), 4.58 (s, 4H, CH2Cl), 2.40 (s, 6H,
2 × ArCH3); 13C NMR (75 MHz, CDCl3): δ = 138.09, 133.61, 133.38, 131.33, 44.50, 18.54.
2.2 4,6-Dimethylisophthalaldehydebenzene (13) [16]. A stirred suspension of 1,3-bis
(chloromethyl)-4,6-dimethylbenzene (12) (80.0 g, 0.394 mol), hexamethylenetetramine (110.5
g, 0.789 mol), ethanol (1000 mL) and water (500 mL) was refluxed for 16 h. The hot reaction
Fig 6. The ligands 4 (orange) and 10ag (green) shown on top of each other from alignment on CID-
10229498. The altered ligand structure induces a relocation of the ligand in the receptor, allowing the phenyl-
substituent on the dihydropyrano[2,3-c]pyrazole N1 in 10ag to participate in several stabilizing hydrophobic
interactions in the β-sheet regions.
doi:10.1371/journal.pone.0162642.g006
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mixture was filtered and the filtrate cooled to room temperature. The pH was adjusted to 1–2
with 4.0 M HCl (aq) and extracted with CH2Cl2 (3 × 700 mL). The combined organic phase
was dried with Na2SO4, filtered and solution concentrated to around 100 mL under reduced
pressure. This resulted in precipitation of 4,6-dimethylisophthal-aldehydebenzene as a white
solid, which was isolated by filtration. Yield: 23.3 g (37%). 1H NMR (300 MHz, CDCl3): δ =
10.25 (d, J = 0.6 Hz, 2H, 2 × CHO), 8.22 (s, 1H, ArH), 7.18 (s, 1H, ArH), 2.70 (d, J = 0.9 Hz,
6H, 2 × ArCH3); 13C NMR (75 MHz, CDCl3): δ = 191.71, 146.38, 136.94, 135.82, 132.78, 20.18;
UPLC-MS (ESI): m/z = 163.1 (M+H)+.
2.3 5-Bromomethyl-2,4-dimethylbenzaldehyde (14). 4,6-Dimethylisophthalaldehyde
(23.3 g, 0.144 mol) was dissolved in EtOH (500 mL) with vigorous stirring at room tempera-
ture. The reaction mixture was then treated with NaBH4 (0.55 g, 0.0146 mol) in one portion.
After stirring for 2 h at room temperature, the solution was treated with another portion of
NaBH4 (0.55 g, 0.0146 mol). After additional 2 h of stirring, the reaction mixture was treated
with a third portion of NaBH4 (0.38 g, 0.010 mol) and the reaction mixture was left with stir-
ring overnight at room temperature. EtOH was removed under reduced pressure and the
remaining oil was treated with boiling water (200 mL) and the mixture cooled to room tem-
perature. Acidification to pH 1–2 with 4.0 M HCl (aq) and treatment with brine (200 mL) and
EtOAc (300 mL) afforded a two-phase system, which was separated. The water phase was
extracted with EtOAc (2 × 200 mL). The combined organic phase was washed with brine (200
mL), dried over Na2SO4, filtered and concentrated in vacuo. The resulting yellow oil was puri-
fied by flash column chromatography on silica gel (eluent: heptane/EtOAc, 95:5) to afford 7.5
g (23%) of 5-bromomethyl-2,4-dimethyl-benzaldehyde (14) as a white solid and 6.0 g (26%) of
recovered 4,6-dimethylisophthalaldehyde (13). 1H NMR (300 MHz, CDCl3): δ = 10.20 (s, 1H,
CHO), 7.74 (s, 1H, ArH), 7.10 (s, 1H, ArH), 4.53 (s, 2H, CH2Br), 2.63 (s, 3H, ArCH3), 2.45 (s,
3H, ArCH3);
13C NMR (75 MHz, CDCl3): δ = 191.82, 143.80, 141.37, 134.54, 134.21, 133.46,
132.64, 31.20, 19.27, 19.13; UPLC-MS (ESI): m/z = 227.1, 229.1 (M+H)+.
2.4 5-((4-Chloro-2-methylphenoxy)methyl)-2,4-dimethylbenz-aldehyde (15)
[17]. 5-Bromomethyl-2,4-dimethylbenzaldehyde (1.0 g, 4.40 mmol) and 4-chloro-2-methyl-
phenol (657 mg, 4.62 mmol) were dissolved in acetonitrile (50 mL) and treated with K2CO3
(912 mg, 6.60 mmol). The suspension was heated to 50˚C with stirring. After 3 h the precipitate
was removed by filtration and the filtrate concentrated in vacuo. Purification by flash column
chromatography on silica gel (eluent: heptane/EtOAc 95:5) to afford the aldehyde 15 as a white
solid. Yield: 1.26 g (99%). 1H NMR (300 MHz, CDCl3): δ = 10.22 (d, J = 0.9 Hz, 1H, CHO), 7.84
(s, 1H, ArH), 7.20–7.07 (m, 2H, ArH), 6.83 (dd, J = 8.0, 1.1 Hz, 1H, ArH), 5.02 (s, 2H, OCH2Ar)
2.65 (s, 3H, ArCH3), 2.40 (s, 3H, ArCH3), 2.22 (d, J = 0.8 Hz, 3H, ArCH3); 13C NMR (75 MHz,
CDCl3): δ = 192.29, 155.38, 143.27, 140.71, 134.17, 133.27, 132.31, 132.26, 130.71, 129.05, 126.49,
125.59, 112.35, 68.23, 19.31, 19.23, 16.38; UPLC-MS (ESI): m/z = 289.2 (M+H)+.
2.5 3-Methyl-1H-pyrazol-5(4H)-one (17) [18]. Ethyl acetoacetate (10.0 g, 0.077 mol) was
dissolved in EtOH (150 mL) and cooled to 0˚C. With stirring the solution was treated drop-
wise with hydrazine hydrate (3.5 g, 0.070 mol). After complete addition the solution was
heated to 60˚C for 3 h and the concentrated in vacuo. The resulting solid was re-crystallized
from Et2O/EtOAc/EtOH to give 17 as a light yellow powder. Yield: 6.2 g (90%).
1H NMR (300
MHz, DMSO-dd): δ = 10.40 (bs, 2H, NH + OH (tautomeric enol form)), 5.21 (s, 1H, CH =
COH (tautomeric enol form)), 2.08 (s, 3H, ArCH3);
13C NMR (75 MHz, CDCl3): δ = 161.22,
139.54, 89.03 (tautomeric enol form), 49.37 (tautomeric keto form), 11.28.
2.6 6-Amino-4-(5-chloro-2-methylphenoxy)methyl)-2,4-dimethylphenyl)-3-methyl-
1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (4) [19]. 5-((4-chloro-2-methylphenoxy)
methyl)-2,4-dimethyl-benzaldehyde (800 mg, 2.77 mmol) and malonitrile (183 mg, 2.77
mmol) was suspended in EtOH (30 mL) and treated with Et3N (280 mg, 2.77 mmol). The
Dihydropyrano-[2,3-c]pyrazoles as a new class of PPARγ partial agonists
PLOS ONE | DOI:10.1371/journal.pone.0162642 February 28, 2017 9 / 19
solution was placed in a pre-heated oil bath (80˚C) and stirred for 2 min., followed by addition
of 3-methyl-1H-pyrazol-5(4H)-one 17 (272 mg, 2.77 mmol. The solution was stirred at 80˚C
for 15 min. Cooling of the reaction to room temperature, resulted in precipitation of 4 as a
white solid, which was isolated by filtration. Yield: 862 mg (72%). 1H NMR (300 MHz, DMSO-
d6): δ = 12.06 (s, 1H, ArNH), 7.21–7.18 (m, 1H, ArH), 7.14 (d, J = 8.8 Hz, 1H, ArH), 7.06 (s, 1H,
ArH), 7.03–6.96 (m, 2H, ArH), 6.82 (s, 2H, ArNH2), 4.99 (s, 2H, ArCH2OAr), 4.80 (s, 1H,
CHAr), 2.28 (s, 3H, ArCH3), 2.24 (s, 3H ArCH3), 2.06 (s, 3H, ArCH3), 1.63 (s, 3H ArCH3);
13C
NMR (75 MHz, DMSO-d6): δ = 160.76, 155.15, 155.09, 139.44, 135.27, 134.38, 134.26, 132.85,
132.19, 129.91, 128.69, 128.40, 126.30, 123.80, 120.88, 113.32, 97.64, 67.80, 56.99, 49.28, 18.53,
17.94, 15.78, 9.57; UPLC-MS (ESI): m/z = 435.3 (M+H)+.
2.7 General synthetic procedure for 1H-pyrazol-5(4H)-one compounds. A solution of
β-ketoester (0.011 mmol) in ethanol (50 mL) was treated with the appropriate hydrazine
(0.011 mmol) at 0˚C. The mixture was allowed to reach room temperature and then heated to
60˚C for 3 h. The solvent was removed in vacuo and the residue purified by recrystallization or
column chromatography.
2.7.1 3-Benzyl-1H-pyrazol-5(4H)-one. The title compound was synthesized from methyl
3-oxo-phenylbutanoate (2.2 g) and hydrazine hydrate (0.44 g) according to the general proce-
dure. The product was purified by recrystallization from toluene/heptane and isolated as a
white/yellow powder. Yield: 0.84 g (42%). M.p.: 190˚C. 1H NMR (300 MHz, DMSO-d6): δ =
3.35 (s, 1H), 3.78 (s, 2H), 5.21 (s, 1H), 7.20–7.32 (m, 5H).
2.8 General synthetic procedure for dihydropyrano[2,3-c]pyrazole compounds (10a-
10ah). The appropriate aldehyde (0.0014 mmol) and malononitrile (0.095 g, 0.0014 mmol)
was suspended in ethanol (20 ml) and treated with Et3N (0.145 g, 0.0014 mmol). The solution
was raised into an preheated oil bath (80˚C) and stirred for 2 min, followed by the addition of
the appropriate 1H-pyrazol-5(4H)-one (0.0014 mmol). After stirring at 80˚C for 15 min, the
solution was cooled to room temperature. The resulting precipitate was isolated by filtration
and washed ethanol.
2.8.1 6-Amino-3-benzyl)-4-(2,5-dimethylphenyl)-1,4-dihydropyrano[2,3-c]pyrazole-
5-carbonitrile (10a). The title compound was synthesized from 2,5-dimethylbenzaldehyde
(0.188 g) and 3-benzyl-1H-pyrazol-5(4H)-one (0.244 g) according to the general procedure.
The product was isolated as a white powder. Yield: 0.512 g (57%). 1H NMR (300 MHz, DMSO-
d6): δ = 12.33 (s, 1H, ArNH), 7.13 (s, 3H, 3 × ArH), 7.04–6.79 (m, 4H, 4 × ArH), 6.80–6.63 (m,
3H, ArH + ArNH2), 4.70 (s, 1H, CHAr), 3.56 (d, J = 15.6 Hz, 1H, ArCHH), 3.27 (d, J = 15.7 Hz,
1H, ArCHH), 2.15 (s, 3H, ArCH3), 2.11 (s, 3H, ArCH3).
13C NMR (75 MHz, DMSO-dd): δ =
160.53, 155.23, 138.08, 137.34, 135.14, 132.02, 130.52, 129.50, 129.43, 128.31, 127.98, 127.43,
126.28, 120.69, 97.59, 56.90, 49.38, 30.36, 20.68, 18.42. IR (neat): 1486, 1597, 1632, 2194, 3088,
3243, 3473. UPLC-MS (ESI): m/z = 357.2 (M+H)+.
2.8.2 6-Amino-3-benzyl-5(o-tolyl)-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile
(10b). The title compound was synthesized from 2-methyl-benzaldehyde (0.172 g) and 3-ben-
zyl-1H-pyrazol-5(4H)-one (0.244 g) according to the general procedure. The product was iso-
lated as a white powder. Yield: 0.312 g (63%). M.p.: 211–213˚C. 1H NMR (300 MHz, DMSO-
d6): δ = 12.34 (s, 1H, ArNH), 7.93–6.15 (m, 11H, 9 × ArH + ArNH2), 4.74 (s, 1H, CHAr), 3.58
(d, J = 16.1 Hz, 1H, ArCHH), 3.24 (d, J = 16.2 Hz, 1H, ArCHH), 2.12 (s, 3H, ArCH3). 13C
NMR (75 MHz, DMSO-d6): δ = 160.59, 155.23, 141.95, 138.07, 137.34, 135.12, 130.62, 129.07,
128.38, 127.99, 126.73, 126.37, 126.31, 120.66, 97.54, 56.76, 56.09, 30.35, 18.77. IR (neat): 1208,
1387, 1640, 2201, 3218, 3312, 3439. UPLC-MS (ESI): m/z = 343.2 (M+H)+.
2.8.3 6-Amino-3-benzyl-4-(2,4-dimethylphenyl)-1,4-dihydropyrano[2,3-c]pyrazole-
5-carbonitrile (10c) [24]. The title compound was synthesized from 2,4-dimethylbenzalde-
hyde (0.188 g) and 3-benzyl-1H-pyrazol-5(4H)-one (0.244 g) according to the general
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procedure. The product was isolated as a white powder. Yield: 0.312 g (63%). M.p.: 211–
213˚C. 1H NMR (300 MHz, DMSO-d6): δ = 12.33 (s, 1H, ArNH), 7.23–7.10 (m, 3H, ArH),
7.01–6.81 (m, 4H, ArH), 6.78–6.65 (m, 3H, ArH + ArNH2), 4.70 (s, 1H, CHAr), 3.56 (d,
J = 15.6 Hz, 1H, ArCHH), 3.27 (d, J = 15.7 Hz, 1H, ArCHH), 2.15 (s, 3H, ArCH3), 2.11 (s, 3H,
ArCH3).
13C NMR (75 MHz, DMSO-d6): δ = 160.49, 155.20, 138.94, 138.05, 137.37, 135.64,
134.87, 131.26, 129.05, 128.33, 127.99, 126.95, 126.24, 120.67, 97.63, 56.94, 50.43, 30.33, 20.58,
18.69. IR (neat): 1208, 1387, 1640, 2201, 3218, 3312, 3439. UPLC-MS (ESI): m/z = 357.2 (M
+H)+.
2.8.4 6-Amino-3-benzyl)-4-(4-methoxy-2,3-dimethylphenyl)-1,4-dihydropyrano[2,3-c]
pyrazole-5-carbonitrile (10d) [25]. The title compound was synthesized from 2,3-dimethyl-
4-methoxybenzaldehyde (0.236 g) and 3-benzyl-1H-pyrazol-5(4H)-one (0.244 g) according to
the general procedure. The product was isolated as a white powder. Yield: 0.428 g (77%). 1H
NMR (300 MHz, DMSO-d6): δ 12.30 (s, 1H, ArNH), 7.18–7.08 (m, 3H, ArH), 6.86–6.69 (m,
6H, 4 (ArH + ArNH2), 4.74 (s, 1H, CHAr), 3.73 (s, 3H, ArOCH3), 3.55 (d, J = 15.7 Hz, 1H,
ArCHH), 3.26 (d, J = 15.7 Hz, 1H, ArCHH), 2.03 (s, 6H, 2 × ArCH3). 13C NMR (101 MHz,
DMSO-d6) δ = 160.3, 155.7, 155.1, 138.0, 137.4, 137.3, 135.0, 128.1, 127.9, 126.1, 120.7, 108.2,
98.3, 58.0, 55.3, 30.3, 14.7, 11.9; IR (neat): 1103, 1399, 2192, 3080, 3236, 3482. UPLC-MS (ESI):
m/z = 387.2 (M+H)+.
2.8.5 6-Amino-4-(4-chlorophenyl)-3-phenyl-1,4-dihydropyrano[2,3-c]pyrazole-5-car-
bonitrile (10e) [26]. The title compound was synthesized from 4-chlorobenzaldehyde (0.197
g) and 3-phenyl-1H-pyrazol-5(4H)-one (0.224 g) according to the general procedure. The
product was isolated as a white powder. Yield: 0.381 g (78%). 1H NMR (300 MHz, DMSO-d6):
δ = 1H-NMR (400 MHz, DMSO-d6): δ = 12.93 (s, 1H, ArNH), 7.50–7.43 (m, 2H, ArH), 7.37–
7.23 (m, 5H, 5 (ArH), 7.17–7.09 (m, 2H, 2 (ArH), 6.98 (s, 2H, ArNH2), 5.06 (s, 1H, CHAr);
13C-NMR (100 MHz, DMSO-d6): δ = 160.56, 156.35, 144.04, 138.47, 131.54, 129.68, 129.07,
128.93, 128.87, 128.74, 126.69, 120.92, 97.40, 58.24, 36.48. UPLC-MS (ESI): m/z = 349.1 (M
+H)+.
2.8.6 6-Amino)-4-(2,4-dichlorophenyl)-3-methyl-1-phenyl-1,4-dihydropyrano[2,3-c]
pyrazole-5-carbonitrile (10f). The title compound was synthesized from from 2,4-dichloro-
benzaldehyde (0.243 g) and 3-phenyl-1H-pyrazol-5(4H)-one (0.224 g) according to the general
procedure. The product was isolated as a white powder. Yield: 0.208 g (39%). 1H NMR (300
MHz, DMSO-d6): δ = 5.45 (s, 1H), 7.00–7.50 (m, 10H), 12.92 (s, 1H). 13C NMR (75 MHz,
DMSO-dd): δ = 33.67, 49.26, 55.96, 96.14, 120.02, 126.13, 127.80, 128.38, 128.58, 131.98,
132.08, 132.97, 138.05, 140.22, 156.10, 160.58. UPLC-MS (ESI): m/z = 383.1 (M+H)+.
2.8.7 6-Amino)-4-(2,5-dimethylphenyl)-3-phenyl-1,4-dihydropyrano[2,3-c]pyrazole-
5-carbonitrile (10g) [25]. The title compound was synthesized from from 2,5-dimethylbenzal-
dehyde (0.243 g) and 3-phenyl-1H-pyrazol-5(4H)-one (0.224 g) according to the general pro-
cedure. The product was isolated as a white powder. Yield: 0.208 g (39%). 1H NMR (300 MHz,
DMSO-d6): δ = 5.45 (s, 1H), 7.00–7.50 (m, 10H), 12.92 (s, 1H). 13C NMR (75 MHz, DMSO-
dd): δ = 33.67, 49.26, 55.96, 96.14, 120.02, 126.13, 127.80, 128.38, 128.58, 131.98, 132.08,
132.97, 138.05, 140.22, 156.10, 160.58. UPLC-MS (ESI): m/z = 343.2 (M+H)+.
2.8.8 6-Amino-3,4-diphenyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (10h)
[27]. The title compound was synthesized from from benzaldehyde (0.149 g) and 3-phenyl-
1H-pyrazol-5(4H)-one (0.224 g) according to the general procedure. The product was isolated
as a white powder. Yield: 0.392 g (89%). 1H NMR (300 MHz, DMSO-d6): δ = 12.84 (s, 1H,
ArNH), 7.44 (d, J = 7.1 Hz, 2H, ArH), 7.33–7.24 (m, 3H, ArH), 7.22–7.17 (m, 2H, ArH), 7.13–
7.07 (m, 3H, ArH), 6.93 (s, 2H + ArNH2), 4.97 (s, 1H, CHAr).
13C NMR (75 MHz, DMSO-d6):
δ = 160.05, 156.03, 144.69, 137.87, 128.63, 128.57, 128.34, 128.31, 127.31, 126.63, 126.20,
120.63, 97.42, 58.26, 36.74. UPLC-MS (ESI): m/z = 315.1 (M+H)+.
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2.8.9 6-Amino-4-(2,4-dimethylphenyl)-3-phenyl-1,4-dihydropyrano[2,3-c]pyrazole-
5-carbonitrile (10i). The title compound was synthesized from from 2,4-dimethylbenzalde-
hyde (0.243 g) and 3-phenyl-1H-pyrazol-5(4H)-one (0.224 g) according to the general proce-
dure. The product was isolated as a white powder. Yield: 0.427 g (89%). 1H NMR (300 MHz,
DMSO-d6): δ = 1H NMR (400 MHz, DMSO-d6): δ = 12.83 (s, 1H, ArNH), 7.64–7.09 (m, 5H,
ArH), 6.89–6.81 (m, 4H, 2 (ArH + 2 (ArNH2), 6.77 (d, J = 7.9, 1H, ArH), 5.15 (s, 1H, CHAr),
2.30 (s, 3H, ArCH3), 2.15 (s, 3H, ArCH3);
13C NMR (100 MHz, DMSO-d6): δ = 159.98, 156.26,
137.70, 135.27, 134.30, 130.99, 128.79, 128.51 (two overlapping signals), 128.27, 127.01, 126.07
(two overlapping signals), 120.63, 97.78, 57.81, 20.46 (two overlapping signals), 18.81.
UPLC-MS (ESI): m/z = 343.2 (M+H)+.
2.8.10 6-Amino-4-(4-methoxy-2,3-dimethylphenyl)-3-phenyl-1,4-dihydropyrano[2,3-c]
pyrazole-5-carbonitrile (10j). The title compound was synthesized from 2,3-dimethyl-
4-methoxybenzaldehyde (0.236 g) and 3-phenyl-1H-pyrazol-5(4H)-one (0.224 g) according to
the general procedure. The product was isolated as a white powder. Yield: 0.401 g (77%). 1H
NMR (300 MHz, DMSO-d6): δ = 12.84 (s, 1H, ArNH), 7.94–7.01 (m, 5H, ArH), 6.78–6.72 (m,
4H, 2 (ArH + ArNH2), 5.23 (s, 1H, CHAr), 3.65 (s, 3H, ArOCH3), 2.26 (s, 3H, ArCH3), 2.05
(s, 3H, ArCH3).
13C NMR (75 MHz, DMSO-d6): δ = 159.87, 156.29, 155.25, 137.56, 134.50,
128.84, 128.51, 128.26, 126.74, 126.10, 123.54, 120.73, 109.81, 108.46, 98.46, 58.54, 55.17, 15.06,
12.06 (two overlapping signals). UPLC-MS (ESI): m/z = 373.2 (M+H)+.
2.8.11 6-Amino-4-(4-fluorophenyl)-3-phenyl-1,4-dihydropyrano[2,3-c]pyrazole-5-car-
bonitrile (10k) [26]. The title compound was synthesized from 4-fluorobenzaldehyde (0.174
g) and 3-phenyl-1H-pyrazol-5(4H)-one (0.224 g) according to the general procedure. The
product was isolated as a white powder. Yield: 0.270 g (58%). 1H NMR (400 MHz, DMSO-d6):
δ = 12.90 (s, 1H, ArNH), 7.48–7.39 (m, 2H, 2 × ArH), 7.34–7.22 (m, 3H, 3 × ArH), 7.17–7.09
(m, 2H, 2 × ArH), 7.06–6.97 (m, 2H, 2× ArH), 6.94 (s, 2H, ArNH2), 5.04 (s, 1H, CHAr); 13C
NMR (100 MHz, DMSO-d6): δ = 160.77 (d, J = 241 Hz), 160.02, 155.88, 140.80 (d, J = 3 Hz),
137.98, 129.20 (d, J = 3 Hz), 128.55, 128.52, 128.35, 126.25, 120.52, 115.02 (d, J = 21 Hz), 97.27,
58.09, 35.91. UPLC-MS (ESI): m/z = 333.1 (M+H)+.
2.8.12 6-Amino-3-phenyl-4-(o-tolyl)-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile
(10l). The title compound was synthesized from 2-methylbenzaldehyde (0.168 g) and 3-phe-
nyl-1H-pyrazol-5(4H)-one (0.224 g) according to the general procedure. The product was iso-
lated as a white powder. Yield: 0.405 g (88%). 1H NMR (300 MHz, DMSO-d6): δ = 12.84 (s,
1H, ArNH), 7.33–7.20 (m, 6H, 5 × ArH), 7.06–6.88 (m, 3H, 3 × ArH), 6.91 (d, J = 2.2 Hz, 1H,
ArH), 6.88 (s, 2H, ArNH2), 5.19 (s, 1H, CHAr), 2.33 (s, 3H, ArCH3);
13C NMR (100 MHz,
DMSO-d6): δ = 160.09, 156.23, 142.67, 137.84, 134.59, 130.36, 128.75, 128.59, 128.46, 128.30,
126.46, 126.31, 126.14, 120.59, 97.70, 57.55, 33.20, 18.88. UPLC-MS (ESI): m/z = 329.1 (M
+H)+.
2.8.13 6-Amino-4-(2,4-dimethylphenyl)-3-propyl-1,4-dihydropyrano[2,3-c]pyrazole-
5-carbonitrile (10m) [25]. The title compound was synthesized from 2,4-dimethylbenzalde-
hyde (0.188 g) and 3-propyl-1H-pyrazol-5(4H)-one (0.177 g) according to the general proce-
dure. The product was isolated as a white powder. Yield: 0.345 g (80%). 1H NMR (300 MHz,
DMSO-d6): δ = 12.07 (s, 1H, ArNH), 6.96–6.85 (m, 3H, ArH), 6.80 (s, 2H, ArNH2), 4.83 (s,
1H, CHAr), 2.20 (s, 6H, 2 × ArCH3), 2.17–1.88 (m, 2H, CH2), 1.29–0.91 (m, 2H, CH2), 0.57
(t, J = 7.3 Hz, 3H, CH3). 13C NMR (75 MHz, DMSO-d6): δ = 160.59, 155.00, 139.54, 139.20,
135.51, 134.73, 131.21, 129.03, 126.86, 120.78, 97.20, 56.94, 26.28, 20.98, 20.57, 18.78, 13.36
(two overlapping aliphatic signals). UPLC-MS (ESI): m/z = 309.2 (M+H)+.
2.8.14 6-Amino-4-(4-chlorophenyl)-3-propyl-1,4-dihydropyrano[2,3-c]pyrazole-5-car-
bonitrile (10n). The title compound was synthesized from 4-chlorobenzaldehyde (0.197 g)
and 3-propyl-1H-pyrazol-5(4H)-one (0.177 g) according to the general procedure. The
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product was isolated as a white powder. Yield: 0.441 g (48%). 1H NMR (300 MHz, DMSO-d6):
δ = 12.15 (s, 1H, ArNH), 7.37 (d, J = 8.4 Hz, 2H, 2 × ArH), 7.19 (d, J = 8.4 Hz, 2H, 2 × ArH),
6.91 (s, 2H, ArNH2), 4.63 (s, 1H, CHAr), 2.17 (ddd, J = 15.0, 8.5, 6.7 Hz, 1H, ArCHHCH2),
2.05 (ddd, J = 14.7, 8.5, 6.4 Hz, 1H, ArCHHCH2), 1.33–1.06 (m, 2H, CH2CH2CH3), 0.63 (t,
J = 7.3 Hz, 3H CH2CH3); 13C NMR (100 MHz, DMSO-d6): δ = 160.75, 154.59, 143.91, 139.82,
131.23, 129.41, 128.40, 120.63, 96.90, 56.97, 35.72, 26.19, 20.95, 13.31. UPLC-MS (ESI): m/z =
315.1 (M+H)+.
2.8.15 6-Amino-4-phenyl-3-propyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile
(10o). The title compound was synthesized from benzaldehyde (0.149 g) and 3-propyl-1H-
pyrazol-5(4H)-one (0.177 g) according to the general procedure. The product was isolated as a
white powder. Yield: 0.441 g (48%). 1H NMR (300 MHz, DMSO-d6): δ = 12.10 (s, 1H, ArNH),
7.36–7.27 (m, 2H, 2 × ArH), 7.25–7.19 (m, 1H, ArH), 7.18–7.13 (m, 2H, 2 × ArH), 6.85 (s, 2H,
ArNH2), 4.58 (s, 1H, CHAr), 2.16 (ddd, J = 14.9, 8.6, 6.6 Hz, 1H, ArCHHCH2), 2.04 (ddd,
J = 14.7, 8.6, 6.4 Hz, 1H, ArCHHCH2), 1.30–1.03 (m, 2H, CH2CH2CH3), 0.61 (t, J = 7.3 Hz,
3H CH2CH3);
13C NMR (100 MHz, DMSO-d6): δ = 160.71, 154.63, 144.87, 139.76, 128.39,
127.52, 126.75, 120.77, 97.33, 57.39, 36.44, 26.21, 20.93, 13.31. UPLC-MS (ESI): m/z = 281.1
(M+H)+.
2.8.16 6-Amino-4-(2,5-dimethylphenyl)-3-propyl-1,4-dihydropyrano[2,3-c]pyrazole-
5-carbonitrile (10p). The title compound was synthesized from 2,5-dimethylbenzaldehyde
(0.188 g) and 3-propyl-1H-pyrazol-5(4H)-one (0.177 g) according to the general procedure.
The product was isolated as a white powder. Yield: 0.216 g (50%). 1H NMR (300 MHz,
DMSO-d6): δ = 12.09 (s, 1H, ArNH), 7.35–6.45 (m, 5H, 3 × ArH + ArNH2), 4.79 (s, 1H,
CHAr), 2.20–1.75 (m, 2H, ArCH2), 2.18 (s, 6H, 2 × ArCH3), 1.39–0.83 (m, 2H, CH2CH2CH3),
0.53 (t, J = 7.7 Hz, 3H, CH2CH3). 13C NMR (75 MHz, DMSO-d6): δ = 160.65, 155.00, 142.08,
139.57, 135.00, 131.89, 130.50, 129.45, 127.42, 127.35, 120.80, 97.21, 56.84, 26.28, 20.94, 20.66,
18.46, 13.31(two overlapping). UPLC-MS (ESI): m/z = 309.2 (M+H)+.
2.8.17 6-Amino-4-(5-((2,3-dichloro-phenoxy)methyl)-2,4-dimethylphenyl)-3-methyl-
1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (10q). The title compound was synthesized
from 5-((3,4-dichlorophenoxy)methyl)-2,4-dimethylbenzaldehyde (0.433 g) and 3-methyl-1H-
pyrazol-5(4H)-one (0.137 g) according to the general procedure. The product was isolated as a
white powder. Yield: 0.529 g (83%). 1H NMR (300 MHz, DMSO-d6): δ = 12.06 (s, 1H, ArNH),
7.51 (m, 1H, ArH), 7.29 (m, 1H, ArH), 7.00 (m, 3H, ArH), 6.83 (m, 2H, ArNH2), 5.02 (s, 2H,
ArCH2OAr), 4.80 (s, 1H, CHAr), 2.23 (s, 6H, 2 × ArCH3), 1.64 (s, 3H ArCH3). 13C NMR (75
MHz, DMSO-d6): δ = 160.74, 157.84, 155.06, 135.31, 135.24, 132.54, 132.03, 131.99, 131.55,
130.86, 129.87, 129.83, 122.51, 120.79, 116.77, 115.95, 97.43, 68.93, 56.74, 40.35, 18.56, 18.04
(two overlapping), 9.59. UPLC-MS (ESI): m/z = 455.1 (M+H)+.
2.8.18 6-Amino-4-(2,4-dimethyl-(5-(phenoxy)methyl)phenyl)-3-methyl-1,4-dihydro-
pyrano[2,3-c]pyrazole-5-carbonitrile (10r). The title compound was synthesized from
2,4-dimethyl-5-phenoxymethyl)-benzaldehyde (0.336 g) and 3-methyl-1H-pyrazol-5(4H)-one
(0.137 g) according to the general procedure. The product was isolated as a white powder.
Yield: 0.400 g (74%). 1H NMR (300 MHz, DMSO-d6): δ = 12.06 (s, 1H, ArNH), 7.38–7.19
(m, 3H, ArH), 7.14–6.87 (m, 4H, ArH), 6.83 (s, 2H, ArNH2), 4.97 (s, 2H, ArCH2OAr), 4.81
(s, 1H, CHAr), 2.25 (s, 6H 2 × ArCH3), 1.64 (s, 3H ArCH3). 13C NMR (75 MHz, DMSO-d6): δ
= 160.74, 158.38, 155.07, 139.21, 135.34, 135.03, 134.83, 132.75, 132.44, 129.72, 129.41, 120.81,
120.67, 114.86, 97.38, 68.04, 56.80, 18.55, 18.04 (two overlapping), 9.62. UPLC-MS (ESI):
m/z = 387.2 (M+H)+.
2.8.19 6-Amino-4-(5-(((5-chloroquinolin-8-yl)oxy)methyl)-2,4-dimethylphenyl)-
3-methyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (10s). The title compound was
synthesized from 5-(((5-chloroquinolin-8-yl)oxy)methyl)-2,4-dimethylbenzaldehyde (0.456 g)
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and 3-methyl-1H-pyrazol-5(4H)-one (0.137 g) according to the general procedure. The prod-
uct was isolated as a white powder. Yield: 0.297 g (63%). 1H NMR (300 MHz, DMSO-d6): δ =
12.04 (s, 1H, ArNH), 9.05–8.82 (m, 1H, ArH), 8.57–8.38 (m, 1H, ArH), 7.80–7.53 (m, 2H,
ArH), 7.28 (m, 1H, ArH), 7.14 (s, 1H, ArH), 7.01 (s, 1H, ArH), 6.83 (s, 2H, ArNH2), 5.19 (s,
2H, ArCH2OAr), 4.86 (s, 1H, CHAr), 2.31 (s, 3H ArCH3), 2.29 (s, 3H ArCH3), 1.70 (s, 3H
ArCH3).
13C NMR (75 MHz, DMSO-d6): δ = 160.75, 155.06, 153.64, 149.86, 140.49, 135.50,
135.03, 132.50, 132.47, 132.17, 130.13, 130.07, 126.69, 126.16, 123.00, 120.83, 120.77, 110.34,
97.50, 69.23, 56.80, 40.08, 18.60, 18.13, 9.66. UPLC-MS (ESI): m/z = 472.2 (M+H)+.
2.8.20 6-Amino-4-(5-(((5-chloronaphthalen-1-yl)oxy)methyl)-2,4-dimethylphenyl)-
3-methyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (10t). The title compound was
synthesized from 5-(((5-chloronaphthalen-1-yl)oxy)methyl)-2,4-dimethylbenz-aldehyde
(0.455 g) and 3-methyl-1H-pyrazol-5(4H)-one (0.137 g) according to the general procedure.
The product was isolated as a white powder. Yield: 0.468 g (71%). 1H NMR (300 MHz,
DMSO-d6): δ = 12.10 (s, 1H, ArNH), 8.25–8.01 (m, 2H, ArH), 7.74–7.56 (m, 2H, ArH), 7.58
(d, J = 8.3 Hz, 2H, ArH), 7.25 (s, 1H, ArH), 7.07 (d, J = 8.4 Hz, 1H, ArH), 7.02 (s, 1H, ArH),
6.88 (s, 2H, ArNH2), 5.19 (s, 2H, ArCH2OAr), 4.86 (s, 1H, CHAr), 2.31 (s, 3H ArCH3), 2.29 (s,
3H ArCH3), 1.70 (s, 3H ArCH3).
13C NMR (75 MHz, DMSO-d6): δ = 160.81, 155.21, 153.04,
135.31, 134.61, 134.57, 134.38, 132.65, 132.37, 130.44, 127.98, 126.62, 126.25, 126.13, 123.67,
122.08, 121.76, 120.91, 109.35, 106.29, 97.69, 68.25, 56.97, 18.55, 18.02 (two overlapping), 9.66.
UPLC-MS (ESI): m/z = 471.2 (M+H)+.
2.8.21 6-Amino-4-(4-chlorophenyl)-3-methyl-1,4-dihydropyrano[2,3-c]pyrazole-5-car-
bonitrile (10u) [28]. The title compound was synthesized from 4-chlorobenzaldehyde (0.197
g) and 3-methyl-1H-pyrazol-5(4H)-one (0.137 g) according to the general procedure. The
product was isolated as a white powder. Yield: 0.301 g (75%). 1H NMR (300 MHz, DMSO-d6):
δ = 12.13 (s, 1H, ArNH), 7.38 (d, J = 8.4 Hz, 2H, 2 × ArH), 7.19 (d, J = 8.5 Hz, 2H, 2 × ArH),
6.92 (s, 2H, ArNH2), 4.63 (s, 1H, CHAr), 1.79 (s, 3H, ArCH3);
13C NMR (75 MHz, DMSO-d6):
δ = 160.90, 154.69, 143.49, 135.65, 131.21, 129.36, 128.45, 120.64, 97.19, 56.74, 35.55, 9.74.
UPLC-MS (ESI): m/z = 287.1 (M+H)+.
2.8.22 6-Amino-3-methyl-4-(o-tolyl)-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile
(10v) [29]. The title compound was synthesized from 2-methylbenzaldehyde (0.168 g) and
3-methyl-1H-pyrazol-5(4H)-one (0.137 g) according to the general procedure. The product
was isolated as a white powder. Yield: 0.295 g (79%). 1H NMR (300 MHz, DMSO-d6): δ =
12.07 (s, 1H, ArNH), 7.18–7.06 (m, 3H, 3 × ArH), (dd, J = 7.7, 2.1 Hz, 1H, ArH), 6.82 (s, 2H,
ArNH2), 4.84 (s, 1H, CHAr), 2.28 (s, 3H, ArCH3), 1.68 (s, 3H, ArCH3);
13C NMR (100 MHz,
DMSO-d6): δ = 160.74, 155.06, 141.86, 135.30, 134.95, 130.46, 128.88, 126.56, 126.30, 120.69,
97.53, 56.73, 33.07, 18.90, 9.52. UPLC-MS (ESI): m/z = 267.1 (M+H)+.
2.8.23 6-Amino-4-(2,4-dichlorophenyl)-3-methyl-1,4-dihydropyrano[2,3-c]pyrazole-
5-carbonitrile (10x) [30]. The title compound was synthesized from 2,4-dichlorobenzaldehyde
(0.243 g) and 3-methyl-1H-pyrazol-5(4H)-one (0.137 g) according to the general procedure.
The product was isolated as a white powder. Yield: 0.062 g (8%). 1H NMR (300 MHz, DMSO-
d6): δ = 1.78 (s, 3H), 5.06 (s, 1H), 7.02 (s, 2H), 7.21 (d, 1H), 7.42 (d, 1H), 7.58 (s, 1H), 12.17 (s,
1H). 13C NMR (75 MHz, DMSO-dd): δ = 9.60, 33.11, 38.69, 55.24, 96.38, 120.33, 128.08,
128.88, 132.16, 132.87, 135.49, 140.13, 154.93, 161.36. IR (neat): 1410, 1585, 2183, 3101, 3246.
UPLC-MS (ESI): m/z = 321.0 (M+H)+.
2.8.24 6-Amino-4-(4-methoxy-2,3-dimethylphenyl)-3-methyl-1,4-dihydropyrano[2,3-c]
pyrazole-5-carbonitrile (10y). The title compound was synthesized from 2,5-dimethylbenzal-
dehyde (0.188 g) and 3-methyl-1H-pyrazol-5(4H)-one (0.137 g) according to the general pro-
cedure. The product was isolated as a white powder. Yield: 0.249 g (58%). 1H NMR (300 MHz,
DMSO-d6): δ = 1.69 (s, 3H), 2.09 (s, 3H), 2.10 (s, 3H), 3.22 (s, 3H), 4.85 (s, 1H), 6.75–6.80 (m,
Dihydropyrano-[2,3-c]pyrazoles as a new class of PPARγ partial agonists
PLOS ONE | DOI:10.1371/journal.pone.0162642 February 28, 2017 14 / 19
4H), 12.04 (s, 1H). 13C NMR (75 MHz, DMSO-dd): δ = 9.69, 10.06, 11.73, 12.01, 14.97, 16.50,
16.68, 30.75, 55.25, 55.53, 55.57, 57.61, 98.19, 99.82, 108.23, 108.37, 120.85, 123.71, 124.98,
125.09, 125.67, 127.24, 134.24, 134.85, 135.31, 154.98, 155.51, 156.90, 157.88, 160.56, 206.56. IR
(neat): 1391, 1596, 2191, 3099, 3221. UPLC-MS (ESI): m/z = 311.1 (M+H)+.
2.8.25 6-Amino)-3-methyl-4-phenyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile
(10z) [31]. The title compound was synthesized from benzaldehyde (0.149 g) and 3-methyl-
1H-pyrazol-5(4H)-one (0.137 g) according to the general procedure. The product was isolated
as a white powder. Yield: 0.297 g (84%). 1H NMR (300 MHz, DMSO-d6): δ = 12.09 (s, 1H,
ArNH), 7.31 (dd, J = 8.0, 6.8 Hz, 2H, ArH), 7.23 (d, J = 7.4 Hz, 1H, ArH), 7.20–7.13(m, 2H,
ArH), 6.86 (s, 2H, ArNH2), 4.59 (s, 1H, CHAr), 1.78 (s, 3H ArCH3);
13C NMR (75 MHz,
DMSO-d6): δ = 160.86, 154.76, 144.45, 135.55, 128.43, 127.46, 126.72, 120.79, 97.64, 57.17,
36.23, 9.74. UPLC-MS (ESI): m/z = 253.1 (M+H)+.
2.8.26 6-Amino-4-(2,4-dimethylphenyl)-3-methyl-1,4-dihydropyrano[2,3-c]pyrazole-
5-carbonitrile (10aa). The title compound was synthesized from 2,4-dimethylbenzaldehyde
(0.188 g) and 3-methyl-1H-pyrazol-5(4H)-one (0.137 g) according to the general procedure.
The product was isolated as a white powder. Yield: 0.330 g (84%). 1H NMR (300 MHz,
DMSO-d6): δ = 12.05 (s, 1H, ArNH), 6.93 (d, J = 2.3 Hz, 2H, ArH), 6.86 (d, J = 8.3 Hz, 1H,
ArH), 6.79 (s, 2H, ArNH2), 4.79 (s, 1H, CHAr), 2.24 (s, 3H ArCH3), 2.23 (s, 3H ArCH3), 1.69
(s, 3H ArCH3);
13C NMR (75 MHz, DMSO-d6): δ = 160.65, 155.05, 135.40, 135.27 (two over-
lapping signals), 134.72, 131.11, 128.85, 126. UPLC-MS (ESI): m/z = 281.1 (M+H)+.
2.8.27 6-Amino-4-(2,5-dimethylphenyl)-3-methyl-1,4-dihydropyrano[2,3-c]pyrazole-
5-carbonitrile (10ab) [32]. The title compound was synthesized from 1,5-dimethylbenzalde-
hyde (0.188 g) and 3-methyl-1H-pyrazol-5(4H)-one (0.137 g) according to the general proce-
dure. The product was isolated as a white powder. Yield: 0.212 g (54%). 1H NMR (300 MHz,
DMSO-d6): δ = 12.05 (s, 1H, ArNH), 7.01 (d, J = 7.7 Hz, 1H, ArH), 6.92 (dd, J = 7.8, 1.8 Hz,
1H, ArH), 6.81 (s, 2H, ArNH2), 6.78 (s, 1H, ArH), 4.79 (s, 1H, CHAr), 2.24 (s, 3H ArCH3),
2.19 (s, 3H ArCH3), 1.69 (s, 3H ArCH3);
13C NMR (75 MHz, DMSO-d6): δ = 160.71, 155.05,
135.30, 135.01, 131.86, 130.40, 129.19, 127.31 (two overlapping signals), 120.72, 97.59, 56.87,
20.67 (two overlapping signals), 18.52, 9.56. UPLC-MS (ESI): m/z = 281.1 (M+H)+.
2.8.28 6-Amino-4-(4-fluorophenyl)-3-methyl-1,4-dihydropyrano[2,3-c]pyrazole-5-car-
bonitrile (10ac) [30]. The title compound was synthesized from 4-fluorobenzaldehyde (0.172
g) and 3-methyl-1H-pyrazol-5(4H)-one (0.137 g) according to the general procedure. The
product was isolated as a white powder. Yield: 0.249 g (58%). 1H NMR (300 MHz, DMSO-d6):
δ = 1.79 (s, 3H), 4.64 (s, 1H), 6.92 (s, 2H), 7.10–7.30 (m, 4H), 12.13 (s, 1H). 13C NMR (75
MHz, DMSO-dd): δ = 9.78, 35.47, 38.69, 38.96, 39.24, 45.01, 49.29, 57.07, 97.53, 115.07, 115.36,
120.77, 129.33, 129.43, 135.67, 140.68, 140.72, 154.72, 159.37, 160.85. IR (neat):1395, 1491,
1591, 2198, 3090, 3226. UPLC-MS (ESI): m/z = 271.1 (M+H)+.
2.8.29 6-Amino-3-methyl-1,4-diphenyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carboni-
trile (10ad) [31]. The title compound was synthesized from benzaldehyde (0.149 g) and 1-phe-
nyl-3-methyl-1H-pyrazol-5(4H)-one (0.244 g) according to the general procedure. The
product was isolated as a white powder. Yield: 0.069 g (15%). 1H NMR (300 MHz, DMSO-d6):
δ = 7.82–7.75 (m, 2H, ArNH), 7.49 (dd, J = 8.5, 7.4 Hz, 2H, ArH), 7.39–7.29 (m, 4H, ArH),
7.29–7.23 (m, 4H, ArH), 7.20 (s, 2H, ArNH2), 4.68 (s, 1H, CHAr), 1.78 (s, 3H ArCH3);
13C
NMR (75 MHz, DMSO-d6): δ = 159.41, 145.25, 143.87, 143.60, 137.52, 129.33, 128.52, 127.77,
127.04, 126.16, 120.00, 119.96, 98.63, 58.16, 36.73, 12.57. UPLC-MS (ESI): m/z = 329.1 (M
+H)+.
2.8.30 6-Amino-1-(4-chlorophenyl)-4-(2,5-dimethylphenyl)-3-methyl-1,4-dihydropyr-
ano[2,3-c]pyrazole-5-carbonitrile (10ae). The title compound was synthesized from
2,5-dimethylbenzaldehyde (0.188 g) and 1-(4-chlorophenyl)-3-methyl-1H-pyrazol-5(4H)-one
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(0.288 g) according to the general procedure. The product was isolated as a white powder.
Yield: 0.040 g (7%). M.p.: 166–168˚C. 1H NMR (300 MHz, DMSO-d6): δ = 1.69 (s, 3H), 2.19
(s, 3H), 2.31 (s, 3H), 4.88 (s, 1H), 6.87 (s, 1H), 6.94 (d, 1H), 7.05 (d, 1H), 7.20 (s, 2H), 7.52 (d,
2H), 7.83 (d, 2H). 13C NMR (75 MHz, DMSO-dd): δ = 12.42, 18.63, 20.69, 49.30, 57.92, 99.00,
119.96, 121.25, 127.71, 129.28, 130.15, 130.41, 132.07, 135.39, 136.47, 140.88, 144.24, 145.70,
159.28. IR (neat): 1383, 1512, 1663, 2198, 3195, 3317, 3465. IR (neat): 1383, 1512, 1663, 2198,
3195, 3317, 3465. UPLC-MS (ESI): m/z = 391.1 (M+H)+.
2.8.31 6-Amino-1-(4-chlorophenyl)-3-methyl-4-(o-tolyl))-1,4-dihydropyrano[2,3-c]pyr-
azole-5-carbonitrile (10af). The title compound was synthesized from 2-methylbenzaldehyde
(0.172 g) and 1-(4-chlorophenyl)-3-methyl-1H-pyrazol-5(4H)-one (0.288 g) according to the
general procedure. The product was isolated as a white powder. Yield: 0.015 g (3%). M.p.:
178˚C. 1H NMR (300 MHz, DMSO-d6): δ = 1.69 (s, 3H), 2.37 (s, 3H), 4.94 (s, 1H), 7.09–7.22
(m, 6H), 7.53 (d, 2H), 7.83 (d, 2H). IR (neat): 1384, 1511, 1662, 2224, 3192, 3332, 3453.
UPLC-MS (ESI): m/z = 377.1 (M+H)+.
2.8.32 6-Amino-4-(2,4-dichlorophenyl)-3-methyl-1-phenyl-1,4-dihydropyrano[2,3-c]
pyrazole-5-carbonitrile (10ag) [32]. The title compound was synthesized from 2,4-dichloro-
benzaldehyde (0.243 g) and 3-methyl-1-phenyl-1H-pyrazol-5(4H)-one (0.242 g) according to
the general procedure. The product was isolated as a white powder. Yield: 0.047 g (8%). 1H
NMR (300 MHz, DMSO-d6): δ = 1.78 (s, 3H), 5.15 (s, 1H), 7.24–7.55 (m, 7H), 7.61 (s, 1H),
7.77 (d, 2H). 13C NMR (75 MHz, DMSO-dd): δ = 12.37, 49.15, 49.23, 56.15, 97.31, 119.56,
120.06, 126.31, 128.13, 128.38, 128.98, 129.36, 132.50, 132.56, 133.09, 137.44, 139.28, 144.28,
144.84, 159.95. IR (neat): 1387, 1557, 2198, 3322, 3456. UPLC-MS (ESI): m/z = 399.1 (M+H)+.
3. Competitive binding assays
IC50 values for respective compounds were determined by competitive binding using time-
resolved fluorescence resonance energy transfer (LanthaScreen, Invitrogen) on a Victor2
microplate reader (PerkinElmer). Briefly, a terbium labeled anti-GST antibody was used to
label purified GST-tagged PPARγ-LBD (ligand binding domain). Energy transfer from ter-
bium to the tracer, a fluorescent pan PPAR agonist, enabled read-out of each test compounds’s
ability to displace the tracer. RFU values from dose-response curves (triplicate sampling) for
test compounds as well as positive controls (rosiglitazone) were then analyzed using GraphPad
Prism [33]. An unrestrained sigmoidal (one-binding site) dose-response curve was fitted to
each data set by linear regression and allowing for determination of IC50 values. All com-
pounds were tested in 10 different concentrations ranging from 3 nM to 500 μM (rosiglitazone
from 0.3 nM to 10 μM).
4. Nuclear receptor-LBD transactivation
Hepa 1–6 cells were grown in minimum essential medium (MEM) (Gibco) supplemented with
10% fetal calf serum (FCS) and antibiotics (62.5 μg/mL penicillin and 100 μg/mL streptomycin).
Mouse embryo fibroblasts (MEFs) were propagated in Dulbeccos Modified Eagle’s Media
(DMEM) supplemented with 10% FCS and antibiotics.
Cells (Hepa 1–6 were used for PPARα whereas MEFs were used for PPARγ, PPARδ and
RXRα transfections) were transfected in solution by Metafectene (Biontex) lipofection, essen-
tially according to the manufacturer’s instructions and seeded in media (MEM or DMEM sup-
plemented with 10% fetal calf serum and antibiotics in 96-well dishes at 24000 cells/cm2. The
transfection plasmid mix included the Gal4-responsive luciferase reporter, the expression vec-
tor for the fusion between the Gal4 DNA-binding domain and the nuclear receptor ligand
binding domains, and a CMV-Renilla luciferase normalization vector (pRL-CMV, Promega).
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Six hours after addition of transfection mix to the cells, the media was changed to media
(MEM or DMEM) supplemented with vehicle (0.1% DMSO), positive control (1 μM Rosiglita-
zone, 30 nM GW7647, 1 μM L165041 or 0.2 μM LG1069 for PPARγ, PPARα, PPARδ and
RXRα, respectively), or compound. Approx. 18 hours later, cells were harvested and lysates
analyzed for Photinus and Renilla luciferase activity by luminometry. All data points were per-
formed in at least triplicate and each sample measured in duplicate. Luminometer raw data
was analyzed in Microsoft Excel spreadsheets and presented as column graphs depicting aver-
age values of triplicates and including standard deviations.
5. Multiple flexible alignment template
Evaluation of the dihydropyrano[2,3-c]pyrazoles 4, 10a-10ah PPARγ binding modes was car-
ried out using a multiple flexible alignment approach. The model was developed, refined and
evaluated using the flexible alignment application of the MOE software. The agonist model set
was generated using the SVL Batch FlexAlign script, based on a PDB compound set of eleven
PPARγ full agonists and twelve seven PPARγ partial aonists. The set of model agonists was
composed of known antidiabetic drugs, including Rosiglitazone (TZD) and Farglitazar (non-
TZD) and other biological relevant agonist with either selective PPARγ or dual PPAR-α/γ,
PPAR-δ/γ selectivity; no pan PPAR agonists were included. The compound set employed in
the development of the PPARγ agonist binding model is given in S2 File in the Supporting
Information. The binding model was then used for the virtual screening of the library of the
dihydropyrano[2,3-c]pyrazoles (4, 10a-10ah). To be a hit, the test ligand pose had to fit the
defined threshold of the binding model (ΔGintr = ΔG–ΔGtorsions, i.e. the torsion scoring term
was excluded) less negative than a threshold value of -10 kcal/mol passed the docking screen,
and the remaining compounds were discarded.
Supporting information
S1 File. General Supporting Information.
(PDF)
S2 File. Model set of compounds for development of binding mode model.
(DOCX)
S3 File. Test set of compounds for validation of binding mode model.
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